From the 'Rhetoric of hope' to the 'Patient-active paradigm' - Strategic positioning of pharmaceutical and biotechnology companies

Technology Analysis and Strategic Management

Volumn 17, Issue 2, 2005, Pages 183-204

  Bower, D Jane ^a  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; INVESTMENT; MANAGEMENT; PHARMACEUTICAL INDUSTRY; STRATEGIC APPROACH;

EID: 21344472962     PISSN: 09537325     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537320500088815     Document Type: Article

References (80)

1. R. Porter, The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present (London, Harper Collins, 1997);
2. R. Porter, Blood and Guts: A Short History of Medicine (New York, Norton, 2004) (first published 2002, Allan Lane).
3. W. Sneader, Drug Discovery: The Evolution of Madern Medicines (Chichester, John Wiley, 1985).
4. Discussed in Porter (1997), op. cit., Ref. 1;
5. M. Bury, Illness narratives: fact or fiction, Sociology of Health and Illness, 23, 2001, pp. 263-285;
6. A. Webster, Innovative health technologies and the social: redefining Health, Medicine and the Body, Current Sociology, 50(3), 2002, pp. 443-457;
7. M. Mulkay, Rhetorics of hope and fear in the great embryo debate, Social Studies of Science, 23(4), 1993, pp. 721-742.
8. M. Mulkay, The Embryo Research Debate: Science and the Politics of Reproduction (Cambridge, Cambridge University Press, 1997).
9. Porter (1997), op. cit., Ref. 1.
10. P. O'Mahony, Introduction, in P. O'Mahony (Ed.), Nature, Risk and Responsibility: Discourses of Biotechnology (London, Macmillan, 1999).
11. Editorial, British Medical Journal, 305, 28 April 2001, p. 322.
12. See, e.g. S. Jones, Genetics in Medicine: Real Promises, Unreal Expectations. Milbank Memorial Fund, 2001, www.milbank.org/ 000712genetics.html.
13. L. Prior, Review article, Sociology of Health and Illness, 23(2), 2001, pp. 251-252.
14. Webster, op. cit., Ref. 3;
15. Porter (2004), op. cit., Ref. 1.
16. Porter (1997, 2004), op. cit., Ref. 1.
17. Porter (1997, 2004), op. cit., Ref. 1.
18. A. Peterson and D. Lupton, The New Public Health: Health and Self in the Age of Risk (London, Sage, 1996).
19. Bury, op. cit., Ref. 3.
20. Porter (1997), op. cit., Ref. 1.
21. Summarised in, e.g. S. Wright, Molecular politics in a global economy, in A. Thackray (Ed.), Private Science: Biotechnology and the Rise of the Molecular Sciences (Philadelphia, PA, University of Pennsylvania Press, 1998),;
22. H. Gottweis, Political economy of British biotechnology, in A. Thackray (Ed.), Private Science: Biotechnology and the Rise of the Molecular Sciences (Philadelphia, PA, University of Pennsylvania Press, 1998), pp 105-130.
23. E. Whittaker and D. J. Bower, A shift to external alliances for product development in the pharmaceutical industry, R&D Management, 24(3), 1994, pp. 249-260;
24. R. Coombs and S. Metcalfe, Innovation in pharmaceuticals: perspectives on the coordination, combination and creation of capabilities, Technology Analysis and Strategic Management, 14(3), 2002, pp. 261-272.
25. A. Thackray, Introduction, in A. Thackray (Ed.), Private Science: Biotechnology and the Rise of the Molecular Sciences (Philadelphia, PA, University of Pennsylvania Press, 1998), pp. 81-104.
26. Reviewed in S. Krimsky, The cultural and symbolic dimensions of agricultural biotechnology, in A. Thackray (Ed.), Private Science: Biotechnology and the Rise of the Molecular Sciences (Philadelphia, PA, University of Pennsylvania Press, 1998);
27. UK Cabinet Office, Field work: weighing up the costs and benefits of GM Crops, Cabinet Office Strategy Unit, London, 2003. www.strategy.gov.uk.
28. See, e.g. Mulkay (1993), op. cit., Ref. 3.
29. Wright, op. cit., Ref. 14.
30. Porter (1997, 2004), op. cit., Ref. 1;
31. Porter (1997, 2004), op. cit., Ref. 1;
32. B. Barnes, Biotechnology as expertise, in P. O'Mahony (Ed.), Nature, Risk and Responsibility: Discourses of Biotechnology (London, Macmillan, 1999).
33. U. Beck et al., Reflexive Modernisation: Politics, Tradition and Aesthetics in the Modern Social Order (Cambridge, Polity Press, 1994);
34. D. Lupton, Risk (London, Routledge, 1999).
35. House of Lords, Regulation of the UK Biotechnology Industry and Global Competitiveness (written evidence received up to 30 April 1993), House of Lords Select Committee on Science and Technology, HL Paper 80-I (London, HMSO, 1993).
36. UK Cabinet Office, op. cit., Ref. 17.
37. Porter (1997), op. cit., Ref. 1.
38. M. Foucault, Power/Knowledge: Selected Interviews and Other Writings, 1972-1977 (New York, Pantheon, 1980).
39. Mulkay (1993, 1997), op. cit., Ref. 3.
40. Mulkay (1993, 1997), op. cit., Ref. 3.
41. I b i d.
42. Department of Health, Stem cell research: medical progress with responsibility, Department of Health, June 2000, www.doh.gov.uk/cegc/ stemcellreport.htm.
43. SCST, Developments in human genetics and embryology, Fourth Report of the Science and technology Committee of the UK Parliament, 2002, www.publications.parliament.uk/pa/cm200102/cmselect/cmsctech/791/ 79103.htm
44. Mulkay (1993, 1997), op. cit., Ref. 3.
45. Mulkay (1993, 1997), op. cit., Ref. 3.
46. R. Porter, Bodies Politic: Disease, Death and Doctors in Britain (London, Reaktion, 2001).
47. Barnes, op. cit., Ref. 20.
48. Porter (1997), op. cit., Ref. 1.
49. K. Davis, Power Under the Microscope (Amsterdam, Foris Publications, 1988);
50. S. Nettleton and J. Watson, The Body in Everyday Life (London, Routledge, 1998);
51. G. Stimson and B. Webb, Going to See the Doctor: The Consultation Process in General Practice (London, Routledge and Kegan Paul, 1975);
52. H. Roberts, The Patient Patients: Women and Their Doctors (London, Pandora, 1985).
53. Bury, op. cit., Ref. 3.
54. Mulkay (1993, 1997), op. cit., Ref. 3.
55. Mulkay (1993, 1997), op. cit., Ref. 3.
56. C. Taylor, Sources of the Self: The Making of the Modern Identity (Cambridge, Cambridge University Press, 1989).
57. Whittaker and Bower, op. cit., Ref. 15;
58. Coombs and Metcalfe, op. cit., Ref. 15.
59. Bury, op. cit., Ref. 3.
60. Mulkay (1993, 1997), op. cit., Ref. 3.
61. Mulkay (1993, 1997), op. cit., Ref. 3.
62. See, e.g. D. J. Bower, Business model fashion and the academic spinout firm, R&D Management, 33(2), 2003, pp. 97-106.
63. Mulkay (1993, 1997), op. cit., Ref. 3.
64. Mulkay (1993, 1997), op. cit., Ref. 3.
65. Lupton, op. cit., Ref. 21.
66. Barnes, op. cit., Ref. 20.
67. Bury, op. cit., Ref. 3.
68. I b i d.
69. Porter (1997), op. cit., Ref. 1.
70. Barnes, op. cit., Ref. 20.
71. Porter (1997), op. cit., Ref. 1.
72. Davis, op. cit., Ref. 34;
73. Nettleton and Watson, op. cit., Ref. 34;
74. Stimson and Webb, op. cit., Ref. 34;
75. Roberts, op. cit., Ref. 34.
76. Barnes, op. cit., Ref. 20.
77. Mulkay (1993, 1997), op. cit., Ref. 3.
78. Mulkay (1993, 1997), op. cit., Ref. 3.
79. S. Parry, The politics of cloning: mapping the rhetorical convergence of embryos and stem cells in parliamentary debates, New Genetics and Society, 22(2), 2003.
80. Foucault, op. cit., Ref. 25.